Stocks · News reference

Lisata Therapeutics Terminates Merger Agreement With Kuva Labs; Termination Due To Kuva Labs' Failure To Obtain Financing, Accept Tendered Shares; Board To Carry Out Strategic Options Including Asset Sale

Jul 24, 2026, 4:20 PMBenzinga Newsdesk

https://www.sec.gov/ix?doc=/Archives/edgar/data/320017/000114036126029541/ef20078724_8k.htm

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Jul 24, 2026, 4:20 PM
Checked: Jul 24, 2026, 4:20 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 4, 2026, 6:27 PMBenzinga Newsdesk
Lisata shares are trading higher after the company announced it is pursuing damages through litigation over Kuva’s breached merger agreement, reviewing strategic alternatives, and cutting costs with a major workforce reduction to preserve cash.
Read original at benzinga
LSTA
BenzingaAug 4, 2026, 11:14 AMBenzinga Newsdesk
Lisata Therapeutics Announces Suit Against Kuva Labs Seeking Damages And $2M Termination Fee; Cuts Approximately 72% Of Full-Time Employees
Lisata has filed suit in the Delaware Court of Chancery against Kuva over Kuva’s breach of the previously-disclosed Agreement and Plan of Merger dated March 6, 2026 (as amended, the "Merger Agreement"), seeking,
Read original at benzinga
LSTA
BenzingaJul 24, 2026, 5:54 PMBenzinga Newsdesk
Lisata Therapeutics shares are trading lower after the company announced it has terminated its merger agreement with Kuva Labs.
Read original at benzinga
LSTA